Related Experiment Video
Updated: May 26, 2026

06:03
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
Adjuvant immunotherapy for non-small cell lung cancer
Zachary C G Tucker1, Benjamin A Laguna, Edmund Moon
1Division of Thoracic Surgery, University of Pennsylvania School of Medicine, 6 White, 3400 Spruce Street, Philadelphia, Pennsylvania 19104, USA. ztucker@tcmedc.org
Cancer Treatment Reviews
|January 10, 2012
Summary
Immunotherapy can help prevent non-small cell lung cancer (NSCLC) recurrence after surgery. This approach targets microscopic tumor cells, improving outcomes for patients with lung cancer.
Area of Science:
- Oncology
- Immunology
- Thoracic Surgery
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality globally.
- Despite surgical resection and adjuvant therapies, over 40% of NSCLC patients experience recurrence.
- Residual microscopic disease post-surgery is a primary driver of treatment failure.
Purpose of the Study:
- To review the role of immunotherapy in managing residual disease after NSCLC surgery.
- To explore how immunotherapy can prevent local and systemic recurrences.
- To discuss the mechanistic basis of immunotherapy for adjuvant treatment in NSCLC.
Main Methods:
- Literature review on immunotherapy strategies for NSCLC.
- Analysis of mechanisms underlying immunotherapy efficacy against minimal disease.
- Examination of current applications of immunotherapy as an adjunct to surgery.
Main Results:
- Immunotherapy shows promise in targeting minimal residual cancer cells.
- The immune system can be harnessed to eliminate microscopic tumor deposits.
- Adjuvant immunotherapy may reduce postoperative recurrence rates in NSCLC.
Conclusions:
- Immunotherapy is a potential strategy to augment surgical treatment for NSCLC.
- Targeting residual disease with immunotherapy can improve long-term patient survival.
- Further research into immunotherapy combinations is warranted for NSCLC treatment.
